NDAORALTABLETPriority Review
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
9
Data completeness
8/8 — Comprehensive
Priority Review
FILSPARI (sparsentan) by Travere Therapeutics is endothelin receptor antagonists [moa]. Approved for focal segmental glomerulosclerosis. First approved in 2023.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FILSPARI (sparsentan) is an oral endothelin receptor antagonist approved in February 2023 for the treatment of IgA nephropathy, a progressive kidney disease. It works by blocking endothelin receptors to reduce proteinuria and slow disease progression. This represents a novel mechanism for addressing a previously difficult-to-treat glomerular disease.
$5MPart D
Peak3.9 years to LOEEarly-stage revenue growth with modest Part D penetration suggests market expansion opportunity and active commercial team hiring.
Mechanism of Action
Endothelin Receptor Antagonists
Pharmacologic Class:
Endothelin Receptor Antagonist
Indications (1)
Clinical Trials (9)
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Started Mar 2026
20 enrolled
Proteinuric Renal DiseaseProteinuric Kidney DiseaseProteinuria+1 more
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Started Oct 2025
20 enrolled
ProteinuriaImmunoglobulin A (IgA) NephropathyFocal Segmental Glomerulosclerosis+1 more
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Started May 2023
48 enrolled
Immunoglobulin A Nephropathy
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Started Aug 2021
67 enrolled
Focal Segmental GlomerulosclerosisMinimal Change DiseaseImmunoglobulin A Nephropathy+2 more
A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
Started Dec 2020
12 enrolled
Immunoglobulin A NephropathyKidney DiseasesGlomerulonephritis, IGA+3 more
Worked on FILSPARI at Travere Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.